EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

BACKGROUND: Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonists are DNA-based molecules that contain several non-methylated CG-motifs for TL...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapp, Kerstin, Volz, Barbara, Curran, Michael A., Oswald, Detlef, Wittig, Burghardt, Schmidt, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323716/
https://www.ncbi.nlm.nih.gov/pubmed/30621769
http://dx.doi.org/10.1186/s40425-018-0470-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323716/
https://www.ncbi.nlm.nih.gov/pubmed/30621769
http://dx.doi.org/10.1186/s40425-018-0470-3

Ejemplares similares